Completed PHASE2 INTERVENTIONAL 2-arm NCT01748695

A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury

A Phase IIa, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study Evaluating the Safety, Tolerability and Efficacy of V158866 in Central Neuropathic Pain Following Spinal Cord Injury

Sponsor: Brigham and Women's Hospital

Conditions Neuropathic Pain Due to Spinal Cord Injury

Interventions Placebo V158866

Updated 9 times since 2017 Last updated: Apr 10, 2017 Started: Jun 30, 2013 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neuropathic Pain Due to Spinal Cord Injury, this trial is completed. The trial is conducted by Brigham and Women's Hospital and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — May 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brigham and Women's Hospital
Vernalis (R&D) Ltd

Data source: Brigham and Women's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States